BACKGROUND: Since the 1960s, group A streptococcus (GAS) has accounted for less than 1% of cases of community-acquired pneumonia. During the past 2 decades there has been a resurgence of invasive GAS infection, but no large study of GAS pneumonia has been performed. METHODS: To determine the clinical and epidemiologic features of GAS pneumonia, we conducted prospective, population-based surveillance of all invasive GAS infection in residents of Ontario from January 1, 1992, through December 31, 1999. RESULTS: Of 2079 cases of invasive GAS infection, 222 (11%) represented GAS pneumonia. The incidence of GAS pneumonia ranged from 0.16 per 100 000 in 1992 to 0.35 per 100 000 in 1999. Most cases were community acquired (81%). Forty-four percent of nursing home-acquired cases occurred during outbreaks. The case fatality rate was 38% for GAS pneumonia, compared with 12% for the entire cohort with invasive GAS infection and 26% for patients with necrotizing fasciitis. The presence of streptococcal toxic shock syndrome (odds ratio, 19; 95% confidence interval, 8.4-42; P =.001) and increasing age (odds ratio per decade, 1.45; 95% confidence interval, 1.2-1.7; P<.001) were associated with fatal outcome. Time to death was rapid, with a median of 2 days despite antimicrobial therapy and supportive measures. CONCLUSIONS: Group A streptococcal pneumonia is a common form of invasive GAS disease but remains an uncommon cause of community-acquired pneumonia. Progression is rapid despite appropriate therapy. The incidence is similar to, and the case fatality rate higher than, that of necrotizing fasciitis.
BACKGROUND: Since the 1960s, group A streptococcus (GAS) has accounted for less than 1% of cases of community-acquired pneumonia. During the past 2 decades there has been a resurgence of invasive GAS infection, but no large study of GASpneumonia has been performed. METHODS: To determine the clinical and epidemiologic features of GASpneumonia, we conducted prospective, population-based surveillance of all invasive GAS infection in residents of Ontario from January 1, 1992, through December 31, 1999. RESULTS: Of 2079 cases of invasive GAS infection, 222 (11%) represented GASpneumonia. The incidence of GASpneumonia ranged from 0.16 per 100 000 in 1992 to 0.35 per 100 000 in 1999. Most cases were community acquired (81%). Forty-four percent of nursing home-acquired cases occurred during outbreaks. The case fatality rate was 38% for GASpneumonia, compared with 12% for the entire cohort with invasive GAS infection and 26% for patients with necrotizing fasciitis. The presence of streptococcal toxic shock syndrome (odds ratio, 19; 95% confidence interval, 8.4-42; P =.001) and increasing age (odds ratio per decade, 1.45; 95% confidence interval, 1.2-1.7; P<.001) were associated with fatal outcome. Time to death was rapid, with a median of 2 days despite antimicrobial therapy and supportive measures. CONCLUSIONS: Group A streptococcal pneumonia is a common form of invasive GAS disease but remains an uncommon cause of community-acquired pneumonia. Progression is rapid despite appropriate therapy. The incidence is similar to, and the case fatality rate higher than, that of necrotizing fasciitis.
Authors: Nicole M Green; Stephen B Beres; Edward A Graviss; James E Allison; Allison J McGeer; Jaana Vuopio-Varkila; Rance B LeFebvre; James M Musser Journal: J Clin Microbiol Date: 2005-08 Impact factor: 5.948
Authors: Michael S Chaussee; Heather R Sandbulte; Margaret J Schuneman; Frank P Depaula; Leslie A Addengast; Evelyn H Schlenker; Victor C Huber Journal: Vaccine Date: 2011-04-08 Impact factor: 3.641
Authors: Andrea L Herrera; Kuta Suso; Stephanie Allison; Abby Simon; Evelyn Schlenker; Victor C Huber; Michael S Chaussee Journal: Microbiology Date: 2017-10 Impact factor: 2.777
Authors: Stephen B Beres; Gail L Sylva; Daniel E Sturdevant; Chanel N Granville; Mengyao Liu; Stacy M Ricklefs; Adeline R Whitney; Larye D Parkins; Nancy P Hoe; Gerald J Adams; Donald E Low; Frank R DeLeo; Allison McGeer; James M Musser Journal: Proc Natl Acad Sci U S A Date: 2004-07-28 Impact factor: 11.205
Authors: Joshua M Klonoski; Heather R Hurtig; Brian A Juber; Margaret J Schuneman; Thomas E Bickett; Joshua M Svendsen; Brandon Burum; Thomas A Penfound; Grigoriy Sereda; James B Dale; Michael S Chaussee; Victor C Huber Journal: Vaccine Date: 2014-07-29 Impact factor: 3.641
Authors: B Vlaminckx; W van Pelt; L Schouls; A van Silfhout; C Elzenaar; E Mascini; J Verhoef; J Schellekens Journal: Eur J Clin Microbiol Infect Dis Date: 2004-05-26 Impact factor: 3.267
Authors: Michael C Thigpen; Chesley L Richards; Ruth Lynfield; Nancy L Barrett; Lee H Harrison; Kathryn E Arnold; Arthur Reingold; Nancy M Bennett; Allen S Craig; Ken Gershman; Paul R Cieslak; Paige Lewis; Carolyn M Greene; Bernard Beall; Chris A Van Beneden Journal: Emerg Infect Dis Date: 2007-12 Impact factor: 6.883